Plenary Session Abstracts
Thomas Powles, Se Hoon Park, Eric Voog, et al.
The abstract concludes: JAVELIN Bladder 100 met its primary objective, demonstrating significantly prolonged OS with 1L maintenance avelumab + BSC vs BSC alone in advanced UC in all randomized patients and patients with PD-L1+ tumors. Efficacy benefits were seen across all prespecified subgroups, and the safety profile of avelumab was consistent with previous studies of monotherapy. Clinical trial information:
NCT02603432.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Seema Ahsan Khan, Fengmin Zhao, Lawrence J. Solin, et al.
The abstract concludes: Early local therapy does not improve survival in patients with de novo metastatic breast cancer and an IPT. Although there was a 2.5-fold higher risk of local disease progression without LRT, LRT of the IPT did not lead to improved HRQOL. Clinical trial information:
NCT01242800.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Shaji Kumar, Susanna J. Jacobus, Adam D. Cohen, et al.
The abstract concludes: In this randomized phase 3 trial, KRd did not improve PFS compared with VRd in NDMM. A significantly higher rate of cardio-pulmonary and renal toxicity was observed with KRd, while neuropathy rates were higher with VRd. VRd remains the standard triplet induction regimen in standard and intermediate risk NDMM, and a suitable backbone for 4 drug combinations. Clinical trial information: NCT01863550.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Thierry Andre, Kai-Keen Shiu, Tae Won Kim, et al.
The abstract concludes:
In this randomized phase 3 trial, KRd did not improve PFS compared with VRd in NDMM. A significantly higher rate of cardio-pulmonary and renal toxicity was observed with KRd, while neuropathy rates were higher with VRd. VRd remains the standard triplet induction regimen in standard and intermediate risk NDMM, and a suitable backbone for 4 drug combinations. Clinical trial information:
NCT01863550.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Roy S. Herbst, Masahiro Tsuboi, Thomas John, et al.
The abstract concludes:
Adjuvant osimertinib is the 1st targeted agent in a global trial to show a statistically significant and clinically meaningful improvement in DFS in pts with stage IB/II/IIIA EGFRm NSCLC after complete tumor resection and adjuvant chemotherapy, when indicated. Adjuvant osimertinib provides an effective new treatment strategy for these pts. Clinical trial information:
NCT02511106.
